“…Compound CPI-169 ( 30 ) inhibits the catalytic activity of PRC2, decreases H3K27me3, and triggers cell cycle arrest and apoptosis in different cell lines. In combination with other drugs, it caused tumor regression in a KARPAS-422 model [91,100]. To date, three compounds are in clinical trials: ( 27 ) for B-cell and follicular lymphomas, sarcoma, mesothelioma and advanced solid tumor treatment (NCT01897571, NCT02601950, NCT02601937, NCT02860286); ( 28 ) for B-cell, follicular, and other non-Hodgkin’s lymphomas, solid tumors, and multiple myeloma (NCT02082977); and CPI-1205 for B-cell lymphoma treatment (NCT02395601).…”